NCT02285816
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAGE-A1/3/4/6
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have solid tumour with positive expression of MAGE-A3
Exclusions: Known symptomatic brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02285816